Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Traditional deep learning models are trained using supervised learning, whereby a model learns representations by mapping an input (eg, retinal photo) with a labelled output (eg, diagnosis of diabetic ...

Patients aged >18 years with either type I or II diabetes mellitus (defined per American Diabetes Association or WHO guidelines) with glycosylated haemoglobin (HbA 1c) values of ≤12% at screening and ...

Diabetic vitreous hemorrhage is linked to neuropathologic changes in specific brain regions, as identified by voxel-based ...

The following is a summary of “Evaluation of macular retinal oximetry across different levels of diabetic retinopathy: a cross sectional study,” published in the January 2025 issue of Ophthalmology by ...

As a retina specialist, one of the most important aspects of eye care I focus on is the prevention and treatment of diabetic retinopathy. This condition is a leading cause of blindness in adults, yet ...

Parapapillary outer temporal retina thickening can reveal diabetic retinopathy development in children with type 1 diabetes mellitus.

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...